|Application ||WB, IHC-P, E|
|Other Accession||NP_085046.4, NP_116206.3, NP_001001851.1|
|Calculated MW||104576 Da|
|Antigen Region||578-606 aa|
|Other Names||Inter-alpha-trypsin inhibitor heavy chain H5, ITI heavy chain H5, ITI-HC5, Inter-alpha-inhibitor heavy chain 5, ITIH5, KIAA1953|
|Target/Specificity||This ITIH5 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 578-606 amino acids from the C-terminal region of human ITIH5.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||ITIH5 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||May act as a tumor suppressor.|
|Tissue Location||Abundantly expressed in placenta. Less abundant expression in mammary gland and ovary. Expression is barely detectable levels in all other tissues tested|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes a heavy chain component of one of the inter-alpha-trypsin inhibitor (ITI) family members. ITI proteins are involved in extracellular matrix stabilization and in the prevention of tumor metastasis. They are also structurally related plasma serine protease inhibitors and are composed of a light chain and varying numbers of heavy chains. This family member is thought to function as a tumor suppressor in breast and thyroid cancers. Alternative splicing results in multiple transcript variants.
Pita, J.M., et al. Br. J. Cancer 101(10):1782-1791(2009)
Veeck, J., et al. Pathologe 29 SUPPL 2, 338-346 (2008) :
Veeck, J., et al. Oncogene 27(6):865-876(2008)
Hamm, A., et al. BMC Cancer 8, 25 (2008) :
Grupe, A., et al. Am. J. Hum. Genet. 78(1):78-88(2006)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.